within Pharmacolibrary.Drugs.ATC.A;

model A10BB31
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 30 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,
    adminCount     = 1,
    Vd             = 0.00027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013833333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Acetohexamide is a first-generation sulfonylurea oral hypoglycemic agent formerly used in the management of type 2 diabetes mellitus to stimulate insulin secretion from pancreatic beta-cells. Its use has largely been discontinued and replaced by newer second-generation sulfonylureas and other antidiabetic agents.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adults; no specific recent clinical PK publication found.</p><h4>References</h4><ol><li><p>Harrower, AD (1996). Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. <i>Clinical pharmacokinetics</i> 31(2) 111–119. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199631020-00003&quot;>10.2165/00003088-199631020-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8853933/&quot;>https://pubmed.ncbi.nlm.nih.gov/8853933</a></p></li><li><p>Ferner, RE, &amp; Chaplin, S (1987). The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. <i>Clinical pharmacokinetics</i> 12(6) 379–401. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198712060-00001&quot;>10.2165/00003088-198712060-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3301149/&quot;>https://pubmed.ncbi.nlm.nih.gov/3301149</a></p></li><li><p>Takada, H, et al., &amp; Imamura, Y (1998). 20beta-hydroxysteroid dehydrogenase catalyzes ketone-reduction of acetohexamide, an oral antidiabetic drug, in liver microsomes of adult male rats. <i>The Journal of pharmacology and experimental therapeutics</i> 287(2) 504–507. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9808673/&quot;>https://pubmed.ncbi.nlm.nih.gov/9808673</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BB31;
